Project Grant HT94252510779
- The Veterans Medical Research Foundation of San Diego was awarded a $4,802,696 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2025, supports a four-year research project titled "A HYBRID I EVALUATION OF INTEGRATIVE HEALTH CARE FOR PTSD". The research aims to transform healthcare for military service members, veterans, and the broader public by conducting advanced biomedical...
- The Defense Health Agency has awarded a $1.632 million Project Grant to the Ocean State Research Institute, Inc., a non-profit research organization, to investigate the long-term outcomes of antipsychotic medication use in U.S. veterans with post-traumatic stress disorder (PTSD). This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. As...
- This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...
- This $997,008 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports a 3-year research project by the Northern California Institute for Research and Education, Inc. (NCIRE) to investigate risk and resilience factors for Alzheimer's disease and related dementias (ADRD) among American Indian and Alaskan Native veterans. The research aims to inform prevention strategies for this population. NCIRE is a...
- The Defense Health Agency awarded a $3.755 million Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to investigate dual orexin antagonist treatment to prevent neurobehavioral sequelae of traumatic brain injury from April 1, 2023 to March 31, 2027. The Military Medical Research and Development program supports innovative medical research to improve warfighter health and transform public healthcare. Under this award,...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $2,449,123 project grant to the Northern California Institute for Research and Education, Inc. (NCIRE) to conduct the "TBI Rehabilitation and Activation in Veterans (TRAIN-VETS)" research project. The grant, awarded on September 1, 2024, will fund a 4-year study to develop and evaluate innovative rehabilitation approaches for improving outcomes for veterans with traumatic...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $6,964,861.00 to The University of Texas Health Science Center at San Antonio to conduct a multi-year longitudinal study focused on military psychological health. The study has five specific aims: Conduct a prospective, longitudinal follow-up of 3,360 previous clinical trial participants treated for PTSD, sleep disorders, or chronic pain. Conduct a...
- This $2,301,698 project grant awarded on September 30, 2023 by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports the "Virtual Insomnia Patients (VIPS) to Accelerate Dissemination of Precision Diagnosis and Treatment of Insomnia" research project. The prime awardee, Arizona State University, will collaborate with sub-awardees including the University of Texas Health Science Center at San Antonio, University of North Texas, and the...
- The U.S. Defense Health Agency awarded a $2,534,532 Project Grant to Rush University Medical Center to evaluate evidence-based options for initial PTSD treatment non-responders. This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a comprehensive range of biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public. The award has a performance period of September 1,...
- This federal Project Grant award of $2,398,281.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program aims to increase access to evidence-based PTSD treatment for military service members and veterans through Behavioral Health Technician-delivered Written Exposure Therapy (WET). The primary awardee, Palo Alto Veterans Institute for Research (Pavir), will oversee the overall project objectives, which include providing WET training to...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,946,999.00 to the Northern California Institute for Research and Education, Inc. (NCIRE) to conduct research on "Suvorexant: Targeting Orexin to Augment Exposure Therapy in Veterans with PTSD and Insomnia". The award commenced on September 1, 2025 and is expected to be completed by August 31, 2029. NCIRE, a non-profit research organization, will investigate the use of the drug suvorexant to enhance the effectiveness of exposure therapy for veterans suffering from post-traumatic stress disorder and insomnia. This research aims to develop innovative medical solutions to address critical health challenges faced by military personnel and the broader population.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.9m | 8/10/25 |